-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Linperlisib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Linperlisib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Linperlisib in Follicular Lymphoma Drug Details: Linperlisib (Intarel) is an antineoplastic agent....
-
Sector Analysis
Sweden General Insurance Market Size and Trends by Line of Business, Distribution, Competitive Landscape and Forecast to 2028
Sweden General Insurance Market Report Overview The gross written premium of the Sweden general insurance market was SEK102.5 billion ($10.1 million) in 2023 and is expected to achieve a CAGR of more than 4% during 2024-2028. The Sweden general insurance market research report provides in-depth market analysis, including insights into the lines of business in the country’s general insurance industry. Furthermore, the report provides a detailed outlook by product category as well as values for key performance indicators, including gross...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danvilostomig in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danvilostomig in Hypopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Danvilostomig in Hypopharyngeal Cancer Drug Details: Danvilostomig (SIB-003) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EQU-001 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EQU-001 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EQU-001 in Epilepsy Drug Details: EQU-001 is under development for the treatment of...
-
Product Insights
NewNet Present Value Model: Moderna Inc’s mRNA-1647
Empower your strategies with our Net Present Value Model: Moderna Inc's mRNA-1647 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Moderna Inc’s mRNA-1010
Empower your strategies with our Net Present Value Model: Moderna Inc's mRNA-1010 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sym-024 in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sym-024 in Malignant Pleural Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sym-024 in Malignant Pleural Mesothelioma Drug Details: Sym-024 is under...
-
Product Insights
Zika Virus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Zika Virus Infections - Drugs In Development, 2023’, provides an overview of the Zika Virus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hypopharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypopharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Hypopharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...